Skip to Content
Merck
  • Design, synthesis, and biological activities of novel Ligustrazine derivatives.

Design, synthesis, and biological activities of novel Ligustrazine derivatives.

Bioorganic & medicinal chemistry (2007-03-27)
Xian-Chao Cheng, Xin-Yong Liu, Wen-Fang Xu, Xiu-Li Guo, Yang Ou
ABSTRACT

A series of novel Ligustrazine derivatives was designed, synthesized, and assayed for their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities. The results showed that most Ligustrazine derivatives exhibited lower EC(50) values for protective effects on the ECV-304 cells damaged by hydrogen peroxide in comparison with Ligustrazine. And some Ligustrazine derivatives presented better antiplatelet aggregation activities than Ligustrazine. The derivatives containing the bisphenylmethyl pharmacophore (7a-c) exhibited highest potency. Compound 7a displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound 7c was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2,3,5,6-Tetramethylpyrazine, 98%
Sigma-Aldrich
2,3,5,6-Tetramethylpyrazine, ≥98%, FG
Sigma-Aldrich
2,3,5,6-Tetramethylpyrazine, natural, ≥98%, FG